StockData
OS Therapies Inc logo

OS Therapies Inc (OSTX) company profile

OSTXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$0.74−0.01 (-0.68%)

Close on Nov 13, 2026Market cap $34.36MP/E –Yield –

About OS Therapies

Pharmaceutical Preparations, SIC 2834

OS Therapies Incorporated is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments for osteosarcoma and other solid tumors. Its pipeline features two core technologies: OST-HER2, an off-the-shelf immunotherapy utilizing an attenuated strain of Listeria monocytogenes to stimulate an immune response against HER2-expressing cancer cells, and a preclinical tunable antibody-drug conjugate platform known as OST-tADC. Beyond human oncology indications such as pediatric osteosarcoma, breast, lung, and esophageal cancers, the company explores veterinary applications in canines. Its intended patient populations include children, young adults, and older patients diagnosed with bone and solid cancers.

The company operates clinical development programs across major hospitals in the United States, including a completed Phase IIb trial conducted across 21 clinical sites in 18 U.S. states. Preclinical research collaborations extend internationally to contract research facilities in Bangalore, India. OS Therapies Incorporated maintains its principal executive offices in Grasonville, Maryland.

Summary of the business section of OS Therapies's latest annual report, written by StockData.

Company profile

Company

Legal name
OS Therapies Inc
Headquarters
Rockville, MD
Address
15825 Shady Grove Road, Suite 135 20850
Phone
(410) 297-7793
Employees
1,000, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
MaloneBailey, LLP, Houston, Texas

Stock & identifiers

Ticker
OSTX
Exchange
NYSE
IPO date
Aug 1, 2024
Shares outstanding
46M, Aug 12, 2026
Public float
$49.60M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1795091
CUSIP
68764Y207
ISIN
US68764Y2072
FIGI
BBG00Y71N7G7
Share class FIGI
BBG00Y71N7H6
EIN
82-5118368

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul A. RomnessPresident and CEO, Director2,473,000
Kerry M. ClemChief Commercial Officer225,000
Knuettel Francis IIChief Financial Officer270,000
Robert PetitSee Remarks200,000
Christopher P. AcevedoChief Financial Officer109,375
Craig EagleDirector–
Olivier Roger JarryDirector–
Theodore F. SearchDirector455,835
John CiccioDirector455,835
Avril Suzette McKean-DieserDirector5,000
Karim GalzahrDirector–
Colin GoddardDirector225,179

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Paul A. Romness
President and Chief Executive Officer
$480.00K$242.17K$1.22M$1.94M+17%
Robert G. Petit
Chief Medical and Scientific Officer
$420.00K–$610.00K$1.03M+13%
Christopher P. Acevedo
Chief Financial Officer
$36.00K–$244.00K$280.00K-1%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 1, 2024
Offer price
$4.00
Securities offered
1,600,000
Gross proceeds
$6.40M
Exchange
NYSE American
First trading day
Aug 1, 2024
First-day close
$2.51-37.3%
Lock-up ends (est.)
Jan 28, 2025

“The initial public offering price is $4.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“of Osteosarcoma is approximately 1,000 individuals annually in the United States and approximately 20,000 globally.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?